OTCMKTS:SFOSF Shanghai Fosun Pharmaceutical (Group) (SFOSF) Stock Price, News & Analysis $1.70 +0.00 (+0.05%) As of 03:08 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest About Shanghai Fosun Pharmaceutical (Group) Stock (OTCMKTS:SFOSF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SFOSF alerts:Sign Up Key Stats Today's Range$1.70▼$1.7050-Day Range$1.70▼$2.0052-Week Range$1.50▼$2.24Volume2,855 shsAverage Volume1,528 shsMarket CapitalizationN/AP/E Ratio1.45Dividend Yield15.88%Price TargetN/AConsensus RatingN/A Company OverviewShanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, anti-infection, API's and intermediate, metabolism, alimentary system, cardiovascular and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services, and investment management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.Read More… Shanghai Fosun Pharmaceutical (Group) Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks2nd Percentile Overall ScoreSFOSF MarketRank™: Shanghai Fosun Pharmaceutical (Group) scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Shanghai Fosun Pharmaceutical (Group). Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Shanghai Fosun Pharmaceutical (Group) is 1.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Shanghai Fosun Pharmaceutical (Group) is 1.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.69.Read more about Shanghai Fosun Pharmaceutical (Group)'s valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverShanghai Fosun Pharmaceutical (Group) has a short interest ratio ("days to cover") of 575, which indicates bearish sentiment.Change versus previous monthShort interest in Shanghai Fosun Pharmaceutical (Group) has recently increased by 194.87%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldShanghai Fosun Pharmaceutical (Group) pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthShanghai Fosun Pharmaceutical (Group) does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Shanghai Fosun Pharmaceutical (Group) is 23.08%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Shanghai Fosun Pharmaceutical (Group)'s dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverShanghai Fosun Pharmaceutical (Group) has a short interest ratio ("days to cover") of 575, which indicates bearish sentiment.Change versus previous monthShort interest in Shanghai Fosun Pharmaceutical (Group) has recently increased by 194.87%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Shanghai Fosun Pharmaceutical (Group) this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shanghai Fosun Pharmaceutical (Group) insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 4.64% of the stock of Shanghai Fosun Pharmaceutical (Group) is held by institutions.Read more about Shanghai Fosun Pharmaceutical (Group)'s insider trading history. Receive SFOSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shanghai Fosun Pharmaceutical (Group) and its competitors with MarketBeat's FREE daily newsletter. Email Address SFOSF Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com SFOSF Stock Analysis - Frequently Asked Questions How have SFOSF shares performed this year? Shanghai Fosun Pharmaceutical (Group)'s stock was trading at $1.8003 at the start of the year. Since then, SFOSF stock has decreased by 5.6% and is now trading at $1.70. View the best growth stocks for 2025 here. How do I buy shares of Shanghai Fosun Pharmaceutical (Group)? Shares of SFOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today1/30/2025Next Earnings (Estimated)3/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:SFOSF CUSIPN/A CIKN/A Webwww.fosunpharma.com Phone86-21-3398-7000FaxN/AEmployees40,370Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio1.45 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:SFOSF) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shanghai Fosun Pharmaceutical (Group) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.